Literature DB >> 2750704

Fine-needle aspiration of mammary lobular carcinoma in situ and atypical lobular hyperplasia.

K E Salhany1, D L Page.   

Abstract

Cytologic features of fine-needle aspirations (FNAs) of the breast from three patients with either lobular carcinoma in situ (LCIS) or atypical lobular hyperplasia (ALH) are described and compared with those in six patients with infiltrating lobular carcinoma (ILC). FNAs of LCIS and ALH were characterized by loosely cohesive cell groups composed of uniform cells with frequent eccentric nuclei, minimal nuclear atypia, and occasional intracytoplasmic lumina. FNAs from ILC had some overlapping features with ALH and LCIS but were generally more cellular and had a higher proportion of noncohesive single cells with more nuclear atypia and pleomorphism. Intracytoplasmic lumina were consistently found in invasive and noninvasive lobular lesions and may represent the most useful cytologic clue for their recognition. FNAs with the above features are atypical and suggestive of ALH or LCIS. Excisional biopsy should be performed in such cases to confirm the presence of ALH or LCIS and to evaluate for ILC.

Entities:  

Mesh:

Year:  1989        PMID: 2750704     DOI: 10.1093/ajcp/92.1.22

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Routine culturing of normal, dysplastic and malignant human mammary epithelial cells from small tissue samples.

Authors:  J T Emerman; D A Wilkinson
Journal:  In Vitro Cell Dev Biol       Date:  1990-12

2.  The importance of intracytoplasmic DPAS positivity in fine needle aspirates of breast lesions.

Authors:  S J Johnson; V Wadehra
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

3.  Stereotactic fine-needle aspiration biopsy for the evaluation of nonpalpable breast lesions: report of an experience based on 2,988 cases.

Authors:  J S Mitnick; M F Vazquez; P I Pressman; M N Harris; D F Roses
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.